253 related articles for article (PubMed ID: 29745874)
21. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
22. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.
Fujimoto M; Hamaguchi Y; Kaji K; Matsushita T; Ichimura Y; Kodera M; Ishiguro N; Ueda-Hayakawa I; Asano Y; Ogawa F; Fujikawa K; Miyagi T; Mabuchi E; Hirose K; Akimoto N; Hatta N; Tsutsui K; Higashi A; Igarashi A; Seishima M; Hasegawa M; Takehara K
Arthritis Rheum; 2012 Feb; 64(2):513-22. PubMed ID: 21987216
[TBL] [Abstract][Full Text] [Related]
23. Possible correlation between serum interleukin-8 levels and the activity of myositis in anti-NXP2 antibody-positive dermatomyositis.
Konishi R; Ichimura Y; Tanaka R; Miyahara H; Okune M; Miyamoto M; Hara M; Iwabuchi A; Takada H; Nakagishi Y; Mizuta M; Kaneko S; Shimizu M; Morio T; Nishino I; Nomura T; Okiyama N
Immunol Med; 2024 Jun; 47(2):100-105. PubMed ID: 38174692
[TBL] [Abstract][Full Text] [Related]
24. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.
Hosono Y; Sie B; Pinal-Fernandez I; Pak K; Mecoli CA; Casal-Dominguez M; Warner BM; Kaplan MJ; Albayda J; Danoff S; Lloyd TE; Paik JJ; Tiniakou E; Aggarwal R; Oddis CV; Moghadam-Kia S; Carmona-Rivera C; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Christopher-Stine L; Larman HB; Mammen AL
Ann Rheum Dis; 2023 Feb; 82(2):246-252. PubMed ID: 36008132
[TBL] [Abstract][Full Text] [Related]
25. Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an "autoimmune tumor marker": A case report.
Karino K; Fujieda Y; Kawamura T; Abe N; Shimoyama S; Kono M; Kato M; Yasuda S; Atsumi T
Medicine (Baltimore); 2018 Dec; 97(49):e13563. PubMed ID: 30544475
[TBL] [Abstract][Full Text] [Related]
26. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study.
Cordel N; Dechelotte B; Jouen F; Lamb JA; Chinoy H; New P; Vencovsky J; Mann H; Galindo-Feria AS; Dani L; Selva-O'Callaghan A; Werth VP; Ravishankar A; Landon-Cardinal O; Tressières B; Boyer O
Rheumatology (Oxford); 2023 Apr; 62(4):1711-1715. PubMed ID: 36250907
[TBL] [Abstract][Full Text] [Related]
27. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis.
Oldroyd A; Sergeant JC; New P; McHugh NJ; Betteridge Z; Lamb JA; Ollier WE; Cooper RG; Chinoy H;
Rheumatology (Oxford); 2019 Apr; 58(4):650-655. PubMed ID: 30535395
[TBL] [Abstract][Full Text] [Related]
28. Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies.
Kim Y; Song KS; Sohn EH; Kang SW; Yoo IS; Shim SC; Yoo SJ; Kim J
Int J Rheum Dis; 2019 Feb; 22(2):314-320. PubMed ID: 30398003
[TBL] [Abstract][Full Text] [Related]
29. Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies.
Ly NTM; Ma N; Ueda-Hayakawa I; Nguyen CTH; Anada R; Okamoto H; Fujimoto M
J Dermatol Sci; 2021 Dec; 104(3):177-184. PubMed ID: 34772582
[TBL] [Abstract][Full Text] [Related]
30. NanoString technology distinguishes anti-TIF-1γ
Preusse C; Eede P; Heinzeling L; Freitag K; Koll R; Froehlich W; Schneider U; Allenbach Y; Benveniste O; Schänzer A; Goebel HH; Stenzel W; Radke J
Brain Pathol; 2021 May; 31(3):e12957. PubMed ID: 34043263
[TBL] [Abstract][Full Text] [Related]
31. Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice.
Mariscal A; Milán M; Baucells A; Martínez MA; Guillen AG; Trallero-Araguás E; Alvarado-Cardenas M; Martínez-Martínez L; Alserawan L; Franco-Leyva T; Sanz-Martínez MT; Viñas-Giménez L; Corominas H; Juárez C; Castellví I; Selva-O'Callaghan A
Front Immunol; 2020; 11():625896. PubMed ID: 33613568
[TBL] [Abstract][Full Text] [Related]
32. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
33. A single-center, retrospective record review of malignancy prevalence in patients with dermatomyositis with anti-transcription intermediary factor 1γ antibodies via line immunoassay versus immunoprecipitation.
Westerdahl S; Hull CM; Clarke JT; Hansen CB; Rhoads JLW
J Am Acad Dermatol; 2021 Feb; 84(2):559-561. PubMed ID: 32619611
[No Abstract] [Full Text] [Related]
34. Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA; Yang Q; Gutierrez-Alamillo L; Pak K; Flegel WA; Mammen AL; Rider LG; Casciola-Rosen LA;
Arthritis Rheumatol; 2024 Apr; 76(4):631-637. PubMed ID: 38059274
[TBL] [Abstract][Full Text] [Related]
35. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
[TBL] [Abstract][Full Text] [Related]
36. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
Fiorentino DF; Mecoli CA; Rosen MC; Chung LS; Christopher-Stine L; Rosen A; Casciola-Rosen L
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040440
[TBL] [Abstract][Full Text] [Related]
37. A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor.
Varedi D; Frigerio A; Scaife C; Hull C
Dermatol Online J; 2019 Mar; 25(3):. PubMed ID: 30982303
[TBL] [Abstract][Full Text] [Related]
38. Age distribution and prevalence in different age groups of four myositis-specific autoantibodies, including anti-ARS, anti-MDA5, anti-Mi-2, and anti-TIF1γ antibodies.
Ueda-Hayakawa I; Tonomura K; Maekawa A; Kaneda E; Arase N; Fujimoto M
J Dermatol; 2023 Aug; 50(8):1058-1062. PubMed ID: 36890683
[TBL] [Abstract][Full Text] [Related]
39. Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy.
Aritomi T; Kido T; Nakano K; Satoh Y; Noguchi S; Jotatsu T; Hanaka T; Satoh M; Tanaka Y; Yatera K
Intern Med; 2019 Feb; 58(3):427-431. PubMed ID: 30210109
[TBL] [Abstract][Full Text] [Related]
40. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.
Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
